Cost-Utility of First-Line Adalimumab and Tocilizumab Monotherapies in Rheumatoid Arthritis Based on Head-To-Head Data
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1506
https://www.valueinhealthjournal.com/article/S1098-3015(13)03411-6/fulltext
Title :
Cost-Utility of First-Line Adalimumab and Tocilizumab Monotherapies in Rheumatoid Arthritis Based on Head-To-Head Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03411-6&doi=10.1016/j.jval.2013.08.1506
First page :
A566
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1350